Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $9

Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $9

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral and lowers the price target from $15 to $9.

byBenzinga Newsdesk

August 3, 2022

1 minute read

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral and lowers the price target from $15 to $9.

Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment

By Lara Goldstein

January 4, 3:31 PM

Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD.

ATAI

News

Chicony Power And Texas Instruments Join Forces To Bring GaN Technology To Next-Generation Energy-Efficient Laptop Power Adapter

By Benzinga Newsdesk

December 14, 2:04 AM

Texas Instruments (TI) (NASDAQ:TXN), a leader in high-voltage semiconductor solutions, today announced that Chicony Power designed in TI's integrated gallium nitride (GaN) technology to power its latest 65-W laptop

TXN